Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Pharmaceutical outsourcing M&A remains robust
October 2020
SHARING OPTIONS:

BOSTON—Capstone Headwaters released its “Pharmaceutical Outsourcing” report in mid-August, reporting that despite disruptions related to the COVID-19 pandemic, merger and acquisition (M&A) activity has remained robust in the pharmaceutical outsourcing industry, with 37 transactions announced or completed so far in 2020. This number slightly outpaces the 36 transactions in 2019. Contract development and manufacturing organizations) and lab/testing providers have comprised the majority of acquisitions year to date—at 35.1 percent and 29.7 percent, respectively.
 
According to Capstone, “The pandemic has emphasized the need for the industry to rethink its reliance on offshore manufacturing and complex global supply chains, as well as how to utilize technology to adopt a more decentralized approach to conducting clinical trials.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.